JP2002517467A - 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 - Google Patents
自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用Info
- Publication number
- JP2002517467A JP2002517467A JP2000553127A JP2000553127A JP2002517467A JP 2002517467 A JP2002517467 A JP 2002517467A JP 2000553127 A JP2000553127 A JP 2000553127A JP 2000553127 A JP2000553127 A JP 2000553127A JP 2002517467 A JP2002517467 A JP 2002517467A
- Authority
- JP
- Japan
- Prior art keywords
- secretin
- effective amount
- individual
- disorder
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 title claims abstract description 128
- 229960002101 secretin Drugs 0.000 title claims abstract description 126
- 108010086019 Secretin Proteins 0.000 title claims abstract description 125
- 102100037505 Secretin Human genes 0.000 title claims abstract description 125
- 230000000926 neurological effect Effects 0.000 title claims abstract description 13
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 12
- 206010003805 Autism Diseases 0.000 title claims description 26
- 208000020706 Autistic disease Diseases 0.000 title claims description 26
- 230000003542 behavioural effect Effects 0.000 title abstract description 10
- 238000011282 treatment Methods 0.000 title description 17
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 208000012902 Nervous system disease Diseases 0.000 claims description 15
- 230000028327 secretion Effects 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 229940076279 serotonin Drugs 0.000 claims description 10
- 239000012876 carrier material Substances 0.000 claims description 9
- 210000001819 pancreatic juice Anatomy 0.000 claims description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 11
- 208000025966 Neurological disease Diseases 0.000 description 9
- 208000029560 autism spectrum disease Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 101800001982 Cholecystokinin Proteins 0.000 description 4
- 102100025841 Cholecystokinin Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000013404 behavioral symptom Diseases 0.000 description 4
- 229940107137 cholecystokinin Drugs 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 201000007197 atypical autism Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001407 pulse-discharge detection Methods 0.000 description 2
- 230000009644 regulation of neurotransmitter levels Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- JWQZOTGHUDZFMU-WIDFLDSMSA-N 17034-35-4 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 JWQZOTGHUDZFMU-WIDFLDSMSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000739506 Homo sapiens Secretin Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8857598P | 1998-06-09 | 1998-06-09 | |
| US60/088,575 | 1998-06-09 | ||
| US09/229,208 US6197746B1 (en) | 1998-05-19 | 1999-01-13 | Method of using secretin for treating autism |
| US09/229,208 | 1999-01-13 | ||
| PCT/US1999/013061 WO1999064059A2 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517467A true JP2002517467A (ja) | 2002-06-18 |
| JP2002517467A5 JP2002517467A5 (https=) | 2007-04-05 |
Family
ID=26778819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553127A Withdrawn JP2002517467A (ja) | 1998-06-09 | 1999-06-09 | 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6197746B1 (https=) |
| EP (1) | EP1085901B1 (https=) |
| JP (1) | JP2002517467A (https=) |
| AT (1) | ATE322283T1 (https=) |
| AU (1) | AU772911B2 (https=) |
| CA (1) | CA2333657A1 (https=) |
| DE (1) | DE69930739D1 (https=) |
| WO (1) | WO1999064059A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008532033A (ja) * | 2005-02-28 | 2008-08-14 | タイポジェン エイエス | 自閉症や脳性麻痺などの精神疾患の予後判定方法 |
| JP2013523769A (ja) * | 2010-03-31 | 2013-06-17 | アベラ ファーマスーティカルズ インコーポレイテッド | 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤 |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2290556A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020314A (en) * | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
| WO2001037801A1 (en) * | 1999-11-22 | 2001-05-31 | Rogoff Joseph A | Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| GB0008326D0 (en) * | 2000-04-06 | 2000-05-24 | Shs International Ltd | Diagnosis and treatment of autism and related disorders |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| AU2001284865A1 (en) * | 2000-08-14 | 2002-02-25 | Joan M. Fallon | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| AU8676301A (en) * | 2000-08-25 | 2002-03-04 | Res Corp Technologies Inc | New uses for amino acid anticonvulsants |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| US6585996B1 (en) | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20050002922A1 (en) * | 2003-03-12 | 2005-01-06 | Richard Boismenu | Use of secretin and secretin analogs to treat affective disorders |
| WO2004080476A1 (en) * | 2003-03-12 | 2004-09-23 | University Of North Carolina At Chapel Hill | Use of secretin in the treatment of schizophrenia |
| WO2004100899A2 (en) * | 2003-05-13 | 2004-11-25 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| US20070034214A1 (en) * | 2005-08-12 | 2007-02-15 | Dochniak Michael J | Method to affect the development of autism spectrum disorders |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) * | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| EP2318035B1 (en) * | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| JP2013507394A (ja) * | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| US8962042B2 (en) | 2010-09-28 | 2015-02-24 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| JP5976100B2 (ja) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | 神経精神障害の処置のための化合物 |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN109908120B (zh) * | 2019-04-22 | 2022-04-19 | 井冈山大学 | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| JPS5029005B2 (https=) * | 1972-05-08 | 1975-09-19 | ||
| US3987014A (en) | 1974-01-10 | 1976-10-19 | Becton, Dickinson And Company | Secretin intermediates and derivatives |
| DE2615229C2 (de) | 1976-04-08 | 1984-05-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung und Reinigung von Sekretin |
| US4086220A (en) | 1976-08-09 | 1978-04-25 | G. D. Searle & Co. | Fragments of secretin |
| DE3066483D1 (en) | 1979-06-13 | 1984-03-15 | Hoechst Ag | Pharmaceutical compositions based on secretin with enhanced and protracted activity, process for their preparation and dihydroxybenzoyl-l-tyrosine |
| NZ196349A (en) | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
| JPS58140024A (ja) | 1982-02-15 | 1983-08-19 | Eisai Co Ltd | セクレチンの精製方法 |
| DE3328793A1 (de) | 1983-08-10 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Herstellung von sekretin |
| SE454513B (sv) | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5008251A (en) | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| EP0681491B1 (en) | 1993-01-29 | 2000-12-13 | Aradigm Corporation | Intrapulmonary delivery of hormones |
| US5527825A (en) | 1994-04-06 | 1996-06-18 | University Of Arkansas | Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
| US5560910A (en) * | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| CA2290556A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| AU745385B2 (en) | 1997-09-11 | 2002-03-21 | Regents Of The University Of California, The | Plus end-directed microtubule motor required for chromosome congression |
-
1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 EP EP99927416A patent/EP1085901B1/en not_active Expired - Lifetime
-
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008532033A (ja) * | 2005-02-28 | 2008-08-14 | タイポジェン エイエス | 自閉症や脳性麻痺などの精神疾患の予後判定方法 |
| JP2013523769A (ja) * | 2010-03-31 | 2013-06-17 | アベラ ファーマスーティカルズ インコーポレイテッド | 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE322283T1 (de) | 2006-04-15 |
| US6790825B2 (en) | 2004-09-14 |
| CA2333657A1 (en) | 1999-12-16 |
| DE69930739D1 (de) | 2006-05-18 |
| US20050249714A1 (en) | 2005-11-10 |
| AU4432299A (en) | 1999-12-30 |
| US20010049353A1 (en) | 2001-12-06 |
| EP1085901B1 (en) | 2006-04-05 |
| EP1085901A2 (en) | 2001-03-28 |
| WO1999064059A3 (en) | 2000-03-02 |
| AU772911B2 (en) | 2004-05-13 |
| US6197746B1 (en) | 2001-03-06 |
| WO1999064059A2 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517467A (ja) | 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 | |
| RU2546520C2 (ru) | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа | |
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| US20230105611A1 (en) | Combination therapy with cgrp antagonists and clostridial derivatives | |
| US20110020279A1 (en) | Rabies cure | |
| JP2002501616A (ja) | 自閉的症候群を鑑別診断および治療する際の助けとするための方法 | |
| TW201119645A (en) | Low frequency glatiramer acetate therapy | |
| CN1711101A (zh) | 孤独症及相似障碍的治疗 | |
| Glaser et al. | Limbic encephalitis | |
| JP2003521462A (ja) | 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用 | |
| EA013591B1 (ru) | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) | |
| BR112019017724A2 (pt) | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla | |
| RU2322985C2 (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| EP4285898A1 (en) | Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same | |
| CN114306207A (zh) | 一种以棒棒糖为载体的口腔给药方法 | |
| RU2192817C2 (ru) | Способ лечения частичной атрофии зрительного нерва | |
| CN1175828C (zh) | 一种抗房劳、抗衰老的药物组合物及其制备方法 | |
| RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
| RU2655763C2 (ru) | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций | |
| CH649710A5 (de) | Psychotropes arzneimittel. | |
| WO2001037801A1 (en) | Secretin and secretin pharmaceuticals for treating attention deficit disorder | |
| IL311532A (en) | Sublingual epinephrine formulations and methods of use | |
| RU2411036C2 (ru) | Способ терапии расстройств эрекции у мужчин | |
| Babayan et al. | Neuroleptics and antipsychotic drugs | |
| SU1438797A1 (ru) | Способ лечени вазомоторного ринита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070206 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070627 |